In cash saving mode, Oncorus cuts trial, staff, lease, and pipeline

In its third quarter report, Oncorus highlighted that it would report updated Phase I data on its lead candidate, an oncolytic virus therapy for solid tumors, before the end of the year.

Now, that readout, pushed back to early 2023, will be the last for ONCR-177. Oncorus announced this morning that it was stopping the clinical trial and cutting off development of the therapy, casting a shadow on its unreleased results.